Showing 4261-4270 of 5646 results for "".
- Oculis Announces Licensing Agreement for Neuroprotective Drug Candidate for Glaucoma from Accure Therapeuticshttps://modernod.com/news/oculis-announces-licensing-agreement-for-neuroprotective-drug-candidate-for-glaucoma-from-accure-therapeutics/2480683/Oculis and Accure Therapeutics announced a licensing agreement granting Oculis exclusive global rights to develop and commercialize ACT-01, a potentially disease-modifying therapy to protect and prevent damage to the optic nerve and retina. Under the terms of the agreement, Accure
- Ocuphire Completes Enrollment in MIRA-4 Pediatric Safety Trial Evaluating Nyxol for Reversal of Mydriasishttps://modernod.com/news/ocuphire-completes-enrollment-in-mira-4-pediatric-safety-trial-evaluating-nyxol-for-reversal-of-mydriasis/2480680/Ocuphire Pharma announced that it has completed enrollment in the MIRA-4 trial evaluating the safety and efficacy of Nyxol eye drops to reverse pharmacologically-induced mydriasis (RM) in 23 pediatric subjects. Ocuphire worked closely with Oculos Develop
- Heru Appoints Former Amazon Executive Brandon Barber as Chief Marketing Officerhttps://modernod.com/news/heru-appoints-former-amazon-executive-brandon-barber-as-chief-marketing-officer/2480679/Heru has announced that veteran tech industry executive Brandon Barber has joined the company as Chief Marketing Officer, effective February 14. “Brandon is a proven strategic and tactical leader whose depth of experience will greatly benefit Heru as we continue to red
- EyePoint Pharmaceuticals Appoints Isabelle Lefebvre as Chief Regulatory Officerhttps://modernod.com/news/eyepoint-pharmaceuticals-appoints-isabelle-lefebvre-as-chief-regulatory-officer/2480678/EyePoint Pharmaceuticals announced the appointment of Isabelle Lefebvre as Chief Regulatory Officer. Ms. Lefebvre brings more than 30 years of global regulatory affairs experience across all phases of drug development, including ophthalmic and ocular conditions. Ms. Lefebvre is su
- Alcon Launches Clareon IOL Portfolio in the UShttps://modernod.com/news/alcon-launches-clareon-iol-portfolio-in-the-us/2480677/Alcon announced the launch of the Clareon family of IOLs in the United States. Utilizing an advanced IOL material, Clareon is designed to deliver consistent visual outcomes and clarity that lasts.[1-7] The Clareon clarity is born out of a glistening-free IOL material that has among
- Santen Establishes its First External Research Laboratory in Europe at the UCL Institute of Ophthalmology in Londonhttps://modernod.com/news/santen-establishes-its-first-external-research-laboratory-in-europe-at-the-ucl-institute-of-ophthalmology-in-london/2480674/Santen, in partnership with UCL Institute of Ophthalmology (IoO), has announced the company’s first external research laboratory in Europe. This development comes following ongoing and committed investment from Santen
- Accure Therapeutics Licenses Neuroprotective Drug Candidate to Oculishttps://modernod.com/news/accure-therapeutics-licenses-neuroprotective-drug-candidate-to-ophthalmology-company-oculus/2480672/Oculis and Accure Therapeutics announced a licensing agreement granting Oculis exclusive global rights to develop and commercialize ACT-01, a potentially disease-modifying therapy to protect and prevent damage to the optic
- Lighthouse Guild to Launch New Technology Center For Blind and Visually Impaired in Manhattanhttps://modernod.com/news/lighthouse-guild-to-launch-new-technology-center-in-manhattan/2480669/Lighthouse Guild is launching its new Technology Center with a special event led by Calvin Roberts, MD, and featuring demonstrations and discussion from Lighthouse Guild clients, community leaders, and vision loss experts,
- Nicox Granted Patent for NCX 470 in China, Extending Coverage to 2039https://modernod.com/news/nicox-granted-patent-for-ncx-470-in-china-extending-coverage-to-2039/2480655/Nicox SA announced that the Chinese National Intellectual Property Administration (CNIPA) has granted the company a formulation patent for NCX 470, its lead product candidate in development for patients with open-angle glaucoma or ocular hypertension, extending coverage in China to 2039. Wit
- Sight Sciences Launches “Don’t Wait for Too Late” Awareness Campaign for Glaucomahttps://modernod.com/news/sight-sciences-launches-dont-wait-for-too-late-awareness-campaign-for-glaucoma/2480649/Sight Sciences announced the launch of its “Don’t Wait for Too Late” educational campaign designed to raise awareness among the optometric community of minimally invasive glaucoma surgery (MIGS) as an earlier surgical intervention for glaucoma.